DIAMEDICA THERAPEUTICS INC (DMAC)
Health Care · Clinical-stage biopharmaceutical / cardiovascular and neurological therapeutics · NASDAQ
A clinical-stage biopharmaceutical company developing DM199, a recombinant human kallikrein-1 protein, to treat acute ischemic stroke, preeclampsia, and fetal growth restriction.
What DIAMEDICA THERAPEUTICS INC does
DiaMedica Therapeutics is a clinical-stage biopharmaceutical company focused on severe ischemic disease. Its lead candidate DM199 (rinvecalinase alfa) is the first recombinant synthetic form of human tissue kallikrein-1 (rhKLK1) being clinically studied in patients; it has received Fast Track Designation from the FDA for acute ischemic stroke treatment. The company is conducting Phase 2 studies in preeclampsia and fetal growth restriction in South Africa, Canada, and the UK, and a Phase 2/3 adaptive trial (ReMEDy2) for acute ischemic stroke globally. DM199 is designed to enhance endothelial health, microcirculatory blood flow, and tissue perfusion by increasing nitric oxide, prostacyclin, and endothelium-derived hyperpolarizing factor production.
Themes: acute ischemic stroke (AIS), preeclampsia / fetal growth restriction, cardiovascular / cerebrovascular disease, tissue kallikrein-based therapy
Fundamentals
- Price$6.52 as of 2026-08-24 close
- Market cap$352M as of 2026-08-24
- 1-year return+6.7% 2025-08-22 close $6.11 → 2026-08-24 close $6.52
- P/En/a negative earnings
- Net margin-1146.8% as of 2026-08-25
- ROE-77.1% as of 2026-08-25
- Debt / equity0.00 as of 2026-08-25
- Beta0.96 as of 2026-08-25
- Last reported earnings2026-08-10 SEC EDGAR Form 8-K (Item 2.02)
How DMAC compares in its sector
- net profit marginbottom 25% 504 covered Health Care peers, as of 2026-08-25
- operating marginbottom 25% 504 covered Health Care peers, as of 2026-08-25
- return on equitybottom 25% 576 covered Health Care peers, as of 2026-08-25
- free cash flow (absolute dollars, latest fiscal year)middle range 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How DIAMEDICA THERAPEUTICS INC looks technically
DIAMEDICA THERAPEUTICS INC (DMAC) is trading 9.6% below its 200-day average, the long-term trend line — a long-term downtrend. Its 50-day average crossed below its 200-day average about 74 trading days ago — a "death cross", a bearish long-term signal. There is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 12, below the 25 that marks a real trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 44, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bearish about 3 trading days ago (its momentum flipped negative). It made a new 20-day low about 19 trading days ago. It is 37.4% below its highest point of the past year. Day-to-day price swings are unusually narrow versus its own recent history — a "Bollinger squeeze" (in the tightest 2% of the past ~6 months), which often precedes a bigger move.
Trend
8
| Distance from the 200-day | it is trading 9.6% below its 200-day average, the long-term trend line — a long-term downtrend | -9.6% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $6.78 | $6.78 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $7.21 | $7.21 |
| Swing structure | its recent peaks and dips disagree — one of them is rising while the other is not, so there is no clean up or down pattern in the swings | mixed — one of the two is not confirming |
| Last swing turn | its last significant turn was a swing high 13 calendar days ago — the swings before that are what the structure reading is measured on | 13 sessions |
| Wave structure | its recent swings can be read as a completed three-part upward correction — a pullback in the A-B-C shape Elliott-wave chartists use; the labelling fails if price closes above 7.1664. It is the only labelling that fits, though not with textbook proportions, and it describes the swings already printed, not what comes next. | possible three-wave upward correction, complete (atypical proportions) |
| Since the 50/200 cross | its 50-day average crossed below its 200-day average about 74 trading days ago — a "death cross", a bearish long-term signal | 74 sessions |
| Trend strength (14-day ADX) | there is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 12, below the 25 that marks a real trend) | 12.1 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 44, neither overbought (above 70) nor oversold (below 30) | 44.0 |
|---|---|---|
| Position in its 14-day range | it is trading in the lower half of its 14-day range ($6.32 to $7.17) — its "stochastic" reading is 24 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 23.6 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bearish about 3 trading days ago (its momentum flipped negative) | 3 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $10.42 | $10.42 |
|---|---|---|
| From the 52-week high | it is 37.4% below its 52-week high (its highest price of the past year) | -37.4% |
| Above the 52-week low | it is 26.8% above its 52-week low (its lowest price of the past year) | +26.9% |
| Below the 52-week high | it is 37.4% below its highest point of the past year | 37.4% |
| Since a 20-day breakout | it made a new 20-day low about 19 trading days ago | 19 sessions |
| Since a 55-day breakout | it made a new 55-day high about 36 trading days ago | 36 sessions |
| All-time high | its highest closing price on record is $44.94 (set on 2012-08-07) | $44.94 |
| Given back of the 52-week move | over the past year its closes ranged ($5.30 to $9.39), and it has given back well over two thirds of its rise from last year’s low — 70% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $6.73 to $6.86. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 70.2% |
| From the all-time high | it is 85.5% below its all-time high | -85.5% |
| Nearest price level | it is trading 1.5% above a support level at $6.42 — a price it turned at six times since 2024-12-20, most recently on 2026-05-27. Since 2024-08-26 it has 10 such levels below the current price and 4 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -1.5% |
| All-time low | its lowest closing price on record is $0.814 (set on 2014-12-05) | $0.814 |
| Above the all-time low | it is 701.0% above its all-time low | +701.0% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are unusually narrow versus its own recent history — a "Bollinger squeeze" (in the tightest 2% of the past ~6 months), which often precedes a bigger move | 2nd percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.3378 between its high and its low — about 5.2% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.3378 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $6.33 and $6.92 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $6.33 – $6.62 – $6.92 |
| Typical daily range (% of price) | its price moves about 5.2% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 5.2% |
| Stretch from the 200-day average | it is trading 2.0 daily ranges below its 200-day average price (9.6% below it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 2.0 daily ranges below its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.53× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
1
| Since a doji | today it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | today |
|---|
Price gaps
2
| Gap at the open | it opened on 2026-08-24 0.2% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | +0.1% |
|---|---|---|
| Gap filled | a 2.1% gap down opened on 2026-07-23 has been "filled" 20 sessions ago — price traded back through the level the gap left behind, and it took 2 sessions to close | 20 sessions ago |
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 6.5 percentage points (the stock lost 3.2% while the market gained 3.3%) | -6.5% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 7.9 percentage points (the stock gained 10.3% while the market gained 2.4%) | +7.9% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 34.8 percentage points (the stock lost 23.7% while the market gained 11.1%) | -34.8% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 11.6 percentage points (the stock gained 6.7% while the market gained 18.3%) | -11.6% |
Signal agreement
2
| Bullish technical signals | 0 of the 9 technical signals we can compute for it are currently in a bullish state — these describe past price behaviour, not a forecast | 0 of 9 |
|---|---|---|
| Bearish technical signals | 5 of the 9 technical signals we can compute for it are currently in a bearish state: a "death cross" — its 50-day average is below its 200-day, trading below its 200-day average, MACD momentum is negative, lagging the market over 6 months, trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 5 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 5.3% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-17 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is moderate, spanning 3.8% of the share price. | -5.3% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 8% below the average price paid so far this year, so the typical buyer over that stretch is under water. That average is $7.12 — a volume-weighted average of daily closes over 156 sessions, not a true tick-by-tick VWAP. | -8.4% |
|---|---|---|
| Vs the average paid since it last reported | the price is 3% below the average price paid since it last reported on 2026-08-10 (its 10-Q), so the typical buyer over that stretch is under water. That average is $6.69 — a volume-weighted average of daily closes over 11 sessions, not a true tick-by-tick VWAP. | -2.6% |
Price levels it has turned at before
DMAC last closed at $6.52 on 2026-08-24. Since 2024-08-26 it has turned at 10 prices below its last close and 4 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $6.42 | Support | 1.5% below the last close | turned there six times · 2024-12-20 to 2026-05-27 |
| $6.64 | Resistance | 1.9% above the last close | turned there twice · 2025-10-01 to 2026-05-11 |
| $6.14 | Support | 5.8% below the last close | turned there twice · 2025-03-17 to 2025-08-22 |
| $7.19 | Resistance | 10.3% above the last close | turned there four times · 2025-10-16 to 2026-08-11 |
| $5.75 | Support | 11.8% below the last close | turned there five times · 2024-12-02 to 2026-05-01 |
| $7.43 | Resistance | 14.0% above the last close | turned there five times · 2025-09-08 to 2026-03-31 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a three-part upward correction — the A-B-C shape chartists use for a pullback — now complete.
This labelling fails — stops being a possible reading at all — if it closes above $7.17.
It is the only labelling that fits these swings, though its proportions are not the textbook ones. It was chosen from 3 labellings that survived the rules, counting shorter readings of the same bars.
This reading has stood for 4 trading days, since 2026-08-19.
Read from daily closes as of 2026-08-24.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading below the 200-day moving average · Pulled back from the 12-month high · MACD just crossed bearish (12/26/9) · in a Bollinger Band volatility squeeze · trendless / choppy (low ADX) · lagging the market | Learn: moving average · golden cross · adx · rsi · macd · breakout · fifty two week high low · bollinger bands
Based on daily closing prices as of 2026-08-24. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.00 mean, 1=Strong Buy…5=Strong Sell) — 4 analysts
- Mean price target$15.50 range $11.00 – $25.00; median $13.00
Analyst estimates, as of 2026-08-19. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for DMAC
- Consensus EPS estimate-$0.2 next reporting period, as of 2026-08-19
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Clinical development risk: DM199 is in early-to-mid stage clinical trials; FDA requested additional non-clinical embryo-fetal development studies in a rabbit model, and preliminary results suggest antibody response in animals, potentially delaying or complicating US regulatory pathway","Competitive and rapidly-changing environment with unpredictable emerging risks; company is unprofitable with significant accumulated deficit and limited cash runway","Regulatory and safety uncertainty: the company is developing a humanized recombinant protein with limited human safety data; regulatory approvals for preeclampsia and acute ischemic stroke are uncertain and may require substantial additional clinical evidence"]
What changed in the latest 10-Q
AI-assisted comparison of DMAC's 10-Q filed 2026-05-06 against the prior one filed 2025-11-12.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing (2026-05-06) adds fetal growth restriction (FGR) to the opening statement of business focus: 'focused on developing novel treatments for preeclampsia (PE), fetal growth restriction (FGR) and acute ischemic stroke (AIS)'
- Newer filing adds description of DM300 as 'patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor' vs. older filing's less specific 'early preclinical stage of development'
- Newer filing adds section header 'Preeclampsia / Fetal Growth Restriction Program and Phase 2 Investigator-Sponsored Study' (older had 'Preeclampsia Program and Phase 2 Investigator-Sponsored Study')
- Newer filing specifies the investigator-sponsored trial is 'being conducted at the Tygerberg Hospital, Cape Town, South Africa'
- Newer filing specifies that interim results showed 'subjects in cohorts 6 through 9, the potentially therapeutic dose levels' exhibited blood pressure reductions
- Newer filing refers to 'DM199 (rinvecalinase alfa; rhKLK1)' with semicolon separator vs. older filing's 'DM199 (rinvecalinase alfa)'
- Newer filing reports financial periods as 'three months ended March 31, 2026 and 2025' reflecting Q1 2026 report vs. older's 'three- and nine-month periods ended September 30, 2025 and 2024'
- Removed:
- Older filing (2025-11-12) contained statement 'Our current focus is on the treatment of PE and AIS' and reference to DM300 being 'in the early preclinical stage of development' which appears revised in newer filing
- Older filing stated 'the first and only rhKLK1 undergoing global clinical development studies' (emphasis on 'only') vs. newer filing's 'the first rhKLK1 undergoing global clinical development studies'
- Older filing included historical enrollment statement 'The first subject in Part 1a was enrolled in the fourth quarter of 2024' which does not appear in newer filing excerpt
- Older filing included statement 'Preparations are underway to initiate Part 1b where up to 30 subjects with PE and expected delivery within 72 hours will be treated' which does not appear in newer filing excerpt
- Older filing included substantive discussion of pre-IND meeting with FDA and animal model studies supporting safety in pregnant humans, not present in newer filing excerpt
- Older filing referenced 'ReMEDy2 clinical trial' section heading and Phase 2/3 adaptive design trial details not present in newer filing excerpt
- Reworded:
- Newer filing: 'focused on developing novel treatments for preeclampsia (PE), fetal growth restriction (FGR) and acute ischemic stroke (AIS)' vs. older: 'committed to improving the lives of people suffering from preeclampsia (PE) and acute ischemic stroke (AIS)' - added FGR and changed tone from 'committed to improving' to 'focused on developing'
- Newer filing: 'KLK1 is an established therapeutic modality in Asia' vs. older: same wording
- Newer filing: mechanism description uses 'believed to enhance' vs. older: 'may enhance'
- Newer filing: 'cardiorenal disease' vs. older: 'cardio renal disease' (spacing change)
- Newer filing: 'We are developing DM199 to address substantial unmet needs' vs. older: 'We are developing DM199 to address two major critical unmet needs'
- Newer filing: 'no approved agents in any global market to safely lower maternal blood pressure and/or reduce the risk of FGR' vs. older: 'no approved agents in any global market to safely lower maternal blood pressure and/or reduce the risk of fetal growth restriction'
- Newer filing: 'fetal growth restriction (FGR, Part 3' vs. older: 'fetal growth restriction (FGR, Part 3' - same but newer uses 'FGR' abbreviation consistently
- Newer filing: 'with clinically-relevant pharmacodynamic activity with no evidence of placental transfer of DM199' vs. older: 'with clinically-relevant pharmacodynamic activity with no evidence of placental transfer'
- Notes:
- The newer filing text is truncated at the end ('The acceptance by the FDA of study data from clinical trials conducted outside the United States may be subject to c'), limiting ability to compare complete sections
- The older filing text is also truncated at the end ('The adaptive design comp'), limiting full comparative analysis of AIS program section
- Both filings cover different reporting periods (Q1 2026 vs. Q3 2025), which accounts for some content differences beyond MD&A wording changes
Risk Factors
The two filings could not be meaningfully compared for this section.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
No open-market insider purchases or sales are on record for DMAC — recent Form 4 activity was compensation-related (awards, option exercises, or tax withholding), not open-market buying or selling.
View full insider trading history → View SEC Form 3/4/5 filingsOnly open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
5 institutional 13F filers reported holding DMAC as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 2,737,508
- Reported value $18,532,928
reported quarterly holdings change (2025-12-31 → 2026-03-31): 1 new, 3 increased, 1 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
DMAC had 5,203,459 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
DMAC had 9.65% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 27.4 days to cover at the same settlement.
- Reported short interest (shares) 5,203,459
- Short interest (% of shares outstanding) 9.65%
- Prior settlement (shares) 5,111,070
- Reported change 1.81%
- Days to cover (reported) 27.4
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Genzyme Corporation (gene/cell therapies)
- Neuralstem (neural regeneration)
- Genoptix (molecular diagnostics)
- Medtronic (stroke intervention devices)
- Stryker (neurovascular solutions)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare DMAC vs…
Frequently asked questions
What does DIAMEDICA THERAPEUTICS INC (DMAC) do?
DiaMedica Therapeutics is a clinical-stage biopharmaceutical company focused on severe ischemic disease. Its lead candidate DM199 (rinvecalinase alfa) is the first recombinant synthetic form of human tissue kallikrein-1 (rhKLK1) being clinically studied in patients; it has received Fast Track Designation from the FDA for acute ischemic stroke treatment.
What sector is DIAMEDICA THERAPEUTICS INC (DMAC) in?
DIAMEDICA THERAPEUTICS INC (DMAC) is classified in the Health Care sector. Its industry is Clinical-stage biopharmaceutical / cardiovascular and neurological therapeutics. It trades on NASDAQ.
Who are DIAMEDICA THERAPEUTICS INC's (DMAC) competitors?
Notable peers of DIAMEDICA THERAPEUTICS INC (DMAC) include Genzyme Corporation (gene/cell therapies), Neuralstem (neural regeneration), Genoptix (molecular diagnostics), Medtronic (stroke intervention devices) and Stryker (neurovascular solutions). This peer set is informational only — not financial advice.
Is DIAMEDICA THERAPEUTICS INC (DMAC) overbought or oversold right now?
DIAMEDICA THERAPEUTICS INC (DMAC) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 44, in the neutral middle (as of 2026-08-24). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on DMAC come from?
Fundamentals and prices come from market data, as of 2026-08-25; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-25. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-24.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.